3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
21
Phase 3
5
Phase 1
5
Phase 1/2
4
Phase 2/3
2
Phase EARLY_PHASE1
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
2
Interventions
Cisplatin
22
pembrolizumab
17
Drug Therapy
16
Carboplatin
15
Paclitaxel
12
Gemcitabine
12
Dexamethasone
12
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
venetoclax
8
atezolizumab
8
Pemetrexed
8
Oxaliplatin
8
Docetaxel
8
Specimen Handling
7
Radiotherapy
7
Nivolumab
7
Cyclophosphamide
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
Methotrexate
6
durvalumab
5
blinatumomab
5
Cytarabine
5
Androgen Antagonists
5
tislelizumab
4
spartalizumab
4
pertuzumab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
tremelimumab
×
Clear all
NCT06904170
2026-02-03
ALICE
UNICANCER
Phase 2/3
Recruiting
196 enrolled
NCT06109272
2025-08-15
LIVIGNO-2
AbbVie
Phase 2/3
Recruiting
660 enrolled